Full data from the Phase III ATHOS-3 Phase III study of La Jolla Pharmaceutical Co.'s synthetic angiotensin II drug LJPC-501 bode well for approval, but nevertheless raise questions about commercial value, some analysts say.
Cleveland Clinic anesthesiologist Ashish Kanna reported full data from the positive trial in the New England Journal of Medicine on...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)